Terms: = Endocrine gland cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E
68 results:
1. Comparison Between Plastic and Metallic Biliary Stent Placement for Preoperative Patients with Pancreatic Head cancer: A Systematic Review and Meta-Analysis.
Endo Y; Tanaka M; Kitago M; Yagi H; Abe Y; Hasegawa Y; Hori S; Nakano Y; Iwasaki E; Kitagawa Y
Ann Surg Oncol; 2024 Feb; 31(2):1319-1327. PubMed ID: 37952017
[TBL] [Abstract] [Full Text] [Related]
2. Thyroid FNA cytology: Impact of the COVID-19 pandemic and vaccination in a Brazilian series.
de Andrade Natal R; Bedin AR; Giongo AA; Dias EM; Paschoalini RB; Volpato AHC; Melo ALA; Santos CC; Delgado ALJ; Dufloth RM; Soares FA; da Cunha Santos G
Cancer Cytopathol; 2024 Jan; 132(1):22-29. PubMed ID: 37747447
[TBL] [Abstract] [Full Text] [Related]
3. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian cancer (MOLTO): A Phase II Trial.
Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
[TBL] [Abstract] [Full Text] [Related]
4. NCOA1/2/3 rearrangements in uterine tumor resembling ovarian sex cord tumor: A clinicopathological and molecular study of 18 cases.
Lu B; Xia Y; Chen J; Tang J; Shao Y; Yu W
Hum Pathol; 2023 May; 135():65-75. PubMed ID: 36646185
[TBL] [Abstract] [Full Text] [Related]
5. Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Milani A; Tuninetti V; Pignata S; Lorusso D; Castaldo D; De Giorgi U; Savarese A; Biglia N; Scandurra G; Mangili G; Di Maio M; Turinetto M; Bellero M; Mammoliti S; Testa S; Scotto G; Purro A; Artioli G; Valabrega G
Tumori; 2023 Oct; 109(5):490-495. PubMed ID: 36609207
[TBL] [Abstract] [Full Text] [Related]
6. Dietary Inflammatory Index, Alternative Healthy Eating Index-2010, Mediterranean Diet Score and the risk of pancreatic cancer.
Afshar N; Hodge AM; Shivappa N; Hébert JR; Giles GG; English DR; Milne RL
Cancer Epidemiol; 2023 Feb; 82():102295. PubMed ID: 36395705
[TBL] [Abstract] [Full Text] [Related]
7. Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian cancer Cells.
Ovejero-Sánchez M; Asensio-Juárez G; González M; Puebla P; Vicente-Manzanares M; Pélaez R; González-Sarmiento R; Herrero AB
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361809
[TBL] [Abstract] [Full Text] [Related]
8. Antiproliferative potential of
Sayed AM; El-Hawary SS; Abdelmohsen UR; Ghareeb MA
Food Funct; 2022 Nov; 13(22):11733-11743. PubMed ID: 36281695
[No Abstract] [Full Text] [Related]
9. Trial sequential meta-analysis of laparoscopic versus open pancreaticoduodenectomy: is it the time to stop the randomization?
Ricci C; Stocco A; Ingaldi C; Alberici L; Serbassi F; De Raffele E; Casadei R
Surg Endosc; 2023 Mar; 37(3):1878-1889. PubMed ID: 36253625
[TBL] [Abstract] [Full Text] [Related]
10. Isolated pancreatic myeloid sarcoma: A potential mimicker of pancreatic adenocarcinoma.
Soni A; Jindal S; Narang V; Singh A; Paul D; Kaur H
Indian J Pathol Microbiol; 2022; 65(3):676-678. PubMed ID: 35900500
[TBL] [Abstract] [Full Text] [Related]
11. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
[TBL] [Abstract] [Full Text] [Related]
12. Gender-Specific Associations Between Metabolic Disorders and Thyroid Nodules: A Cross-Sectional Population-Based Study from China.
Zhang F; Teng D; Tong N; Wang G; Li Y; Yu X; Shan Z; Teng W
Thyroid; 2022 May; 32(5):571-580. PubMed ID: 35317620
[No Abstract] [Full Text] [Related]
13. An update on the safety of olaparib for treating ovarian cancer.
Cottrell K; Clark CL; Penson RT
Expert Opin Drug Saf; 2022 Apr; 21(4):447-451. PubMed ID: 35212587
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Trillsch F; Mahner S; Ataseven B; Asher R; Aryal N; Dubot C; Clamp A; Penson RT; Oza A; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; Denys H; Lowe ES; Lee CK; Pujade-Lauraine E
Gynecol Oncol; 2022 Apr; 165(1):40-48. PubMed ID: 35115180
[TBL] [Abstract] [Full Text] [Related]
15. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
[TBL] [Abstract] [Full Text] [Related]
16. Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian cancer.
Ajjarapu SM; Tiwari A; Taj G; Singh DB; Singh S; Kumar S
BMC Pharmacol Toxicol; 2021 Nov; 22(1):68. PubMed ID: 34727985
[TBL] [Abstract] [Full Text] [Related]
17. Infiltration of thyroid papillary cancer tissue with myeloid leukemic cells: a case report.
Sözen M; Vural Ç; Selek A; Kiraz U; Cantürk Z; Çetinarslan B; Gezer E; Köksalan D
World J Surg Oncol; 2021 Jul; 19(1):225. PubMed ID: 34325712
[TBL] [Abstract] [Full Text] [Related]
18. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Kesavan M; Grover P; Lam WS; Claringbold PG; Turner JH
Endocr Relat Cancer; 2021 Jun; 28(7):521-527. PubMed ID: 34010146
[TBL] [Abstract] [Full Text] [Related]
19. Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
González M; Ovejero-Sánchez M; Vicente-Blázquez A; Álvarez R; Herrero AB; Medarde M; González-Sarmiento R; Peláez R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673002
[TBL] [Abstract] [Full Text] [Related]
20. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract] [Full Text] [Related]
[Next]
